KR20150061041A - 인간 ｏｘ４０ 수용체에 대한 결합 분자 - Google Patents

인간 ｏｘ４０ 수용체에 대한 결합 분자 Download PDF

Info

Publication number
KR20150061041A
KR20150061041A KR1020157013715A KR20157013715A KR20150061041A KR 20150061041 A KR20150061041 A KR 20150061041A KR 1020157013715 A KR1020157013715 A KR 1020157013715A KR 20157013715 A KR20157013715 A KR 20157013715A KR 20150061041 A KR20150061041 A KR 20150061041A
Authority
KR
South Korea
Prior art keywords
antibody
ox40r
human
ser
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020157013715A
Other languages
English (en)
Korean (ko)
Inventor
징 민
얀리 유
로리 프란시스 핀
바레트 리차드 틸
웨이 리아오
로날드 폴 글레이듀
아빈드 라즈펄
티모시 조세프 파라디스
페터 브람스
브리지트 드벅스
이 유
크리스토퍼 토이
하이디 엔. 레블란크
하이춘 후앙
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40552119&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20150061041(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 브리스톨-마이어스 스큅 컴퍼니, 화이자 인코포레이티드 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Publication of KR20150061041A publication Critical patent/KR20150061041A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020157013715A 2007-12-14 2008-12-11 인간 ｏｘ４０ 수용체에 대한 결합 분자 Ceased KR20150061041A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1394707P 2007-12-14 2007-12-14
US61/013,947 2007-12-14
PCT/US2008/086417 WO2009079335A1 (en) 2007-12-14 2008-12-11 Binding molecules to the human ox40 receptor

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020107015527A Division KR101577843B1 (ko) 2007-12-14 2008-12-11 인간 ｏｘ４０ 수용체에 대한 결합 분자

Publications (1)

Publication Number Publication Date
KR20150061041A true KR20150061041A (ko) 2015-06-03

Family

ID=40552119

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020157013715A Ceased KR20150061041A (ko) 2007-12-14 2008-12-11 인간 ｏｘ４０ 수용체에 대한 결합 분자
KR1020107015527A Expired - Fee Related KR101577843B1 (ko) 2007-12-14 2008-12-11 인간 ｏｘ４０ 수용체에 대한 결합 분자

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020107015527A Expired - Fee Related KR101577843B1 (ko) 2007-12-14 2008-12-11 인간 ｏｘ４０ 수용체에 대한 결합 분자

Country Status (29)

Country Link
US (7) US7960515B2 (enExample)
EP (4) EP3239178A1 (enExample)
JP (4) JP5761997B2 (enExample)
KR (2) KR20150061041A (enExample)
CN (1) CN101918447B (enExample)
AR (2) AR069681A1 (enExample)
AU (1) AU2008338591B8 (enExample)
BR (1) BRPI0820875B1 (enExample)
CA (2) CA2707773C (enExample)
CL (1) CL2008003706A1 (enExample)
CO (1) CO6280541A2 (enExample)
DK (3) DK2242771T3 (enExample)
ES (3) ES2526887T3 (enExample)
HR (1) HRP20141188T8 (enExample)
HU (1) HUE032735T2 (enExample)
IL (3) IL206297A (enExample)
MX (1) MX2010006466A (enExample)
PA (1) PA8807601A1 (enExample)
PE (1) PE20091269A1 (enExample)
PH (1) PH12015500806A1 (enExample)
PL (2) PL2594590T3 (enExample)
PT (3) PT2851374T (enExample)
RU (1) RU2010129045A (enExample)
SG (2) SG10201604770VA (enExample)
SI (3) SI2851374T1 (enExample)
TW (1) TW200932268A (enExample)
UY (1) UY31533A1 (enExample)
WO (1) WO2009079335A1 (enExample)
ZA (1) ZA201003579B (enExample)

Families Citing this family (189)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2938527B2 (ja) * 1990-07-30 1999-08-23 株式会社リコー 自動原稿給送装置
HUE032735T2 (en) * 2007-12-14 2017-10-30 Bristol Myers Squibb Co Binding molecules for the human OX40 receptor
EP2398498B1 (en) 2009-02-17 2018-09-05 UCB Biopharma SPRL Antibody molecules having specificity for human ox40
WO2012015696A1 (en) * 2010-07-26 2012-02-02 Baylor Research Institute Thymic stromal lymphopoietin (tslp) and ox40 ligand in cancer
PL2609118T3 (pl) 2010-08-23 2017-07-31 Board Of Regents, The University Of Texas System Przeciwciała anty-OX40 i sposoby ich stosowania
CN103221428B (zh) 2010-09-09 2016-02-10 辉瑞公司 4-1bb结合分子
EP2731677B1 (en) * 2011-07-11 2018-04-18 Glenmark Pharmaceuticals S.A. Antibodies that bind to ox40 and their uses
KR101685262B1 (ko) * 2011-08-23 2016-12-21 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 항-ｏｘ４０ 항체 및 이의 사용 방법
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
US9758591B2 (en) 2012-08-24 2017-09-12 The Regents Of The University Of California Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
WO2014089113A1 (en) 2012-12-03 2014-06-12 Bristol-Myers Squibb Company Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
NZ712903A (en) * 2013-03-18 2018-07-27 Biocerox Prod Bv Humanized anti-cd134 (ox40) antibodies and uses thereof
CN105612175B (zh) 2013-08-08 2023-05-09 赛腾制药 基于IL-15和IL-15Rαsushi结构域的调节因子
CA2934028A1 (en) 2013-12-17 2015-06-25 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
KR102127408B1 (ko) * 2014-01-29 2020-06-29 삼성전자주식회사 항 Her3 scFv 단편 및 이를 포함하는 항 c-Met/항 Her3 이중 특이 항체
HRP20192285T1 (hr) * 2014-03-31 2020-03-06 F. Hoffmann - La Roche Ag Anti-ox40 protutijela i postupci uporabe
RU2016142476A (ru) 2014-03-31 2018-05-07 Дженентек, Инк. Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
EP4140485A1 (en) 2014-07-11 2023-03-01 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of hiv
TW201619200A (zh) * 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
CN107109484B (zh) 2014-11-03 2021-12-14 豪夫迈·罗氏有限公司 用于ox40激动剂治疗的功效预测和评估的方法和生物标志物
AU2015343337A1 (en) 2014-11-03 2017-06-15 Genentech, Inc. Assays for detecting T cell immune subsets and methods of use thereof
KR20170072343A (ko) 2014-11-06 2017-06-26 제넨테크, 인크. Ox40 결합 효능제 및 tigit 억제제를 포함하는 병용 요법
MX2017006320A (es) 2014-11-17 2017-08-10 Genentech Inc Terapia combinada que comprende agonistas de unión de ox40 y antagonistas de unión del eje de pd-1.
RS63384B1 (sr) * 2015-01-08 2022-08-31 BioNTech SE Agonistička sredstva za vezivanje tnf receptora
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
CN112263677A (zh) 2015-02-26 2021-01-26 默克专利股份公司 用于治疗癌症的pd-1/pd-l1抑制剂
HRP20230046T1 (hr) 2015-03-03 2023-03-03 Kymab Limited Protutijela, upotreba i postupci
MX2017012805A (es) 2015-04-07 2018-04-11 Genentech Inc Complejo de unión a antígenos con actividad agonista y métodos de uso.
PH12017502013B1 (en) * 2015-05-07 2022-07-22 Agenus Inc Anti-ox40 antibodies and methods of use thereof
US11008396B2 (en) * 2015-05-21 2021-05-18 Alligator Bioscience Ab Polypeptides
GB201509338D0 (en) * 2015-05-29 2015-07-15 Bergenbio As Combination therapy
UY36687A (es) * 2015-05-29 2016-11-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Anticuerpos contra ox40 y sus usos
MY193229A (en) 2015-06-16 2022-09-26 Merck Patent GmbH Pd-l1 antagonist combination treatments
EP3112381A1 (en) * 2015-07-01 2017-01-04 FONDAZIONE IRCCS Istituto Nazionale dei Tumori Bispecific antibodies for use in cancer immunotherapy
US20180230431A1 (en) 2015-08-07 2018-08-16 Glaxosmithkline Intellectual Property Development Limited Combination Therapy
HK1257270A1 (zh) 2015-09-15 2019-10-18 Gilead Sciences, Inc. 用於治療hiv的toll樣受體(tlr)調節劑
US20190022092A1 (en) 2015-09-15 2019-01-24 Acerta Pharma B.V. Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist
MA43017A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Anticorps bispécifiques spécifiques d'un récepteur de co-stimulation du tnf
CN108137684B (zh) * 2015-10-15 2022-03-08 苏州丁孚靶点生物技术有限公司 抗ox40抗体及其应用
SMT202200118T1 (it) 2015-11-03 2022-05-12 Janssen Biotech Inc Anticorpi che legano specificamente pd-1 e loro usi
EP4015537A1 (en) 2015-12-01 2022-06-22 GlaxoSmithKline Intellectual Property Development Limited Combination treatments and uses and methods thereof
SG10201912984WA (en) 2015-12-02 2020-03-30 Agenus Inc Antibodies and methods of use thereof
CA3006930A1 (en) 2015-12-03 2017-06-08 Glaxosmithkline Intellectual Property Development Limited Cyclic purine dinucleotides as modulators of sting
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
JP6783312B2 (ja) * 2016-01-25 2020-11-11 ファイザー・インク がんを処置するためのｏｘ４０アゴニストおよび４−１ｂｂアゴニストモノクローナル抗体の組み合わせ
WO2017153952A1 (en) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives
ES2781474T3 (es) 2016-04-07 2020-09-02 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas útiles como moduladores de proteínas
PE20181884A1 (es) 2016-04-07 2018-12-07 Glaxosmithkline Ip Dev Ltd Amidas heterociclicas utiles como moduladores de proteinas
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
SG11201809560QA (en) 2016-05-05 2018-11-29 Glaxosmithkline Ip No 2 Ltd Enhancer of zeste homolog 2 inhibitors
TW201831513A (zh) 2016-06-20 2018-09-01 Ｆ星貝塔有限公司 結合物件(一)
MX2018016330A (es) 2016-06-27 2020-02-17 Univ California Combinaciones para tratamiento del cáncer.
CN117143247A (zh) * 2016-07-19 2023-12-01 伊班绰斯有限责任公司 双特异性蛋白质及其制备方法
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
WO2018015879A1 (en) 2016-07-20 2018-01-25 Glaxosmithkline Intellectual Property Development Limited Isoquinoline derivatives as perk inhibitors
US11649289B2 (en) 2016-08-04 2023-05-16 Glaxosmithkline Intellectual Property Development Limited Anti-ICOS and anti-PD-1 antibody combination therapy
EP3494139B1 (en) 2016-08-05 2022-01-12 F. Hoffmann-La Roche AG Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
CN109843916B (zh) 2016-08-12 2023-10-31 詹森生物科技公司 具有增强的激动活性的Fc工程化抗TNFR超家族成员抗体及其使用方法
CN109863170B (zh) 2016-08-12 2024-08-16 詹森生物科技公司 具有增强的激动作用和效应子功能的工程化抗体及其他含Fc结构域分子
AU2017324983B2 (en) * 2016-09-07 2025-03-20 Saksin Lifesciences Pvt Ltd Synthetic antibodies against VEGF and their uses
AU2017339856B2 (en) 2016-10-06 2024-09-05 Merck Patent Gmbh Dosing regimen of avelumab for the treatment of cancer
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
EP3538152A4 (en) 2016-11-09 2020-09-30 Agenus Inc. ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES, AND PROCESSES FOR USE
JP2020511407A (ja) 2016-12-01 2020-04-16 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 併用療法
WO2018100534A1 (en) 2016-12-01 2018-06-07 Glaxosmithkline Intellectual Property Development Limited Combination therapy
PE20191403A1 (es) 2016-12-15 2019-10-04 Abbvie Biotherapeutics Inc Anticuerpos anti-ox40 y sus usos
WO2018115003A2 (en) 2016-12-19 2018-06-28 Glenmark Pharmaceuticals S.A. Novel tnfr agonists and uses thereof
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
JP7780248B2 (ja) 2017-01-06 2025-12-04 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍壊死因子受容体スーパーファミリー（ｔｎｆｒｓｆ）アゴニストによる腫瘍浸潤リンパ球（ｔｉｌ）の拡大培養及びｔｉｌとｔｎｆｒｓｆアゴニストとの治療的併用
US20200062735A1 (en) 2017-02-27 2020-02-27 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
CN108623686A (zh) * 2017-03-25 2018-10-09 信达生物制药(苏州)有限公司 抗ox40抗体及其用途
AR112072A1 (es) 2017-06-05 2019-09-18 Iovance Biotherapeutics Inc Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario
EP3635011A1 (en) 2017-06-09 2020-04-15 GlaxoSmithKline Intellectual Property Development Limited Combination therapy with icos agonist and ox40 agonist to treat cancer
WO2018225034A1 (en) 2017-06-09 2018-12-13 Glaxosmithkline Intellectual Property Development Limited Combination therapy with icos agonist and ox40 agonist to treat cancer
WO2019021208A1 (en) 2017-07-27 2019-01-31 Glaxosmithkline Intellectual Property Development Limited USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
CN111511762B (zh) 2017-08-21 2025-05-06 天演药业公司 抗cd137分子及其用途
US20210363265A1 (en) * 2017-08-24 2021-11-25 Invenra Inc. Multivalent receptor-clustering agonist antibody constructs
US10363272B2 (en) * 2017-08-31 2019-07-30 Io Therapeutics, Inc. RAR selective agonists in combination with immune modulators for cancer immunotherapy
WO2019053617A1 (en) 2017-09-12 2019-03-21 Glaxosmithkline Intellectual Property Development Limited CHEMICAL COMPOUNDS
CN111417630B (zh) 2017-10-05 2023-06-06 葛兰素史克知识产权开发有限公司 干扰素基因刺激因子(sting)的调节剂
EP3692033A1 (en) 2017-10-05 2020-08-12 GlaxoSmithKline Intellectual Property Development Limited Modulators of stimulator of interferon genes (sting) useful in treating hiv
CN111601883B (zh) 2017-11-17 2024-06-21 艾欧凡斯生物治疗公司 由细针抽吸物和小活检物扩增til
WO2019100320A1 (en) * 2017-11-24 2019-05-31 Eucure (Beijing) Biopharma Co., Ltd Anti-ox40 antibodies and uses thereof
US11142579B2 (en) 2017-12-06 2021-10-12 Sorrento Therapeutics, Inc. Variant antibodies that bind OX40
AU2018394939B2 (en) 2017-12-29 2022-02-24 Ap Biosciences, Inc. Monospecific and bispecific proteins with immune checkpoint regulation for cancer therapy
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
US12104172B2 (en) 2018-01-08 2024-10-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific t-cells
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
WO2019148444A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
MA51875A (fr) 2018-02-13 2020-12-23 Iovance Biotherapeutics Inc Expansion de lymphocytes infiltrant les tumeurs (til) avec des antagonistes du récepteur a2a de l'adénosine et combinaisons thérapeutiques de til et d'antagonistes du récepteur a2a de l'adénosine
MA52533A (fr) 2018-04-27 2021-03-03 Iovance Biotherapeutics Inc Procédé en circuit fermé pour l'amplification et l'edition de gènes de lymphocytes d'infiltration des tumeurs et leurs utilisations en immunothérapie
CN114685665B (zh) * 2018-05-11 2025-02-14 无锡药明生物技术股份有限公司 抗ox40的全人抗体及其制备方法和用途
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
EP3796983A2 (en) 2018-05-23 2021-03-31 Pfizer Inc. Antibodies specific for gucy2c and uses thereof
PL3797121T3 (pl) 2018-05-23 2024-09-23 Pfizer Inc. Przeciwciała swoiste dla CD3 i ich zastosowania
US12344672B2 (en) 2018-07-12 2025-07-01 Invox Pharma Limited Antibody molecules that bind PD-L1 and CD137
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
MX2021000399A (es) 2018-07-12 2021-05-27 F Star Therapeutics Ltd Moleculas de anticuerpo que se unen a cd137 y ox40.
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
US20210277135A1 (en) 2018-07-13 2021-09-09 Bristol-Myers Squibb Company Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a method of treating a cancer or a solid tumor
TW202031273A (zh) 2018-08-31 2020-09-01 美商艾歐凡斯生物治療公司 抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療
EP3852524B1 (en) 2018-09-20 2023-06-28 Iovance Biotherapeutics, Inc. Expansion of tils from cryopreserved tumor samples
KR20210091213A (ko) 2018-11-05 2021-07-21 이오반스 바이오테라퓨틱스, 인크. 종양 침윤 림프구의 생성 방법 및 면역치료법에서 이의 용도
CA3118493A1 (en) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathway inhibitors
JP7688575B2 (ja) 2018-11-05 2025-06-04 アイオバンス バイオセラピューティクス，インコーポレイテッド 抗ｐｄ－１抗体に対して不応性のｎｓｃｌｃ患者の治療
US20230039976A1 (en) 2018-11-05 2023-02-09 Iovance Biotherapeutics, Inc. Selection of improved tumor reactive t-cells
JP7440509B2 (ja) * 2018-11-09 2024-02-28 ベス イスラエル デアコネス メディカル センター Ｃｄｃｐ１－標的化療法
US20220193131A1 (en) 2018-12-19 2022-06-23 Iovance Biotherapeutics, Inc. Methods of Expanding Tumor Infiltrating Lymphocytes Using Engineered Cytokine Receptor Pairs and Uses Thereof
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
WO2020160375A1 (en) 2019-02-01 2020-08-06 Glaxosmithkline Intellectual Property Development Limited Combination treatments for cancer comprising belantamab mafodotin and an anti ox40 antibody and uses and methods thereof
CA3134144A1 (en) 2019-03-29 2020-10-08 Myst Therapeutics, Llc Ex vivo methods for producing a t cell therapeutic and related compositions and methods
WO2020232029A1 (en) 2019-05-13 2020-11-19 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
EP3976043A1 (en) 2019-05-24 2022-04-06 Pfizer Inc. Combination therapies using cdk inhibitors
CN113874036A (zh) 2019-05-24 2021-12-31 辉瑞公司 使用cdk抑制剂的联合治疗
CN110172090B (zh) * 2019-06-03 2020-04-03 中山标佳生物科技有限公司 Cd134单克隆抗体及其制备方法和癌症治疗中的应用
MA56397A (fr) 2019-06-26 2022-05-04 Glaxosmithkline Ip Dev Ltd Protéines de liaison à l'il1rap
US11339159B2 (en) 2019-07-17 2022-05-24 Pfizer Inc. Toll-like receptor agonists
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
WO2021043961A1 (en) 2019-09-06 2021-03-11 Glaxosmithkline Intellectual Property Development Limited Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
EP4034562B1 (en) 2019-09-27 2025-10-29 GlaxoSmithKline Intellectual Property Development Limited Antigen binding proteins
EP4048295A1 (en) 2019-10-25 2022-08-31 Iovance Biotherapeutics, Inc. Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
IL293350A (en) 2019-11-27 2022-07-01 Myst Therapeutics Llc Method of producing tumor-reactive t cell composition using modulatory agents
JP7749561B2 (ja) 2019-12-11 2025-10-06 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球（ｔｉｌ）の産生のためのプロセス及びそれを使用する方法
JP7369297B2 (ja) 2019-12-17 2023-10-25 ファイザー・インク Ｃｄ４７、ｐｄ－ｌ１に特異的な抗体、およびその使用
US20230043985A1 (en) 2019-12-18 2023-02-09 Pfizer Inc. Once daily cancer treatment regimen with a prmt5 inhibitor
CN114981265B (zh) 2019-12-18 2025-01-03 Ctxt私人有限公司 化合物
US20230067202A1 (en) 2020-01-28 2023-03-02 Glaxosmithkline Intellectual Property Development Limited Combination Treatments and Uses and Methods Thereof
CN115427438A (zh) 2020-02-27 2022-12-02 迈斯特治疗公司 肿瘤反应性t细胞的离体富集和扩增的方法及其相关组合物
WO2021181233A2 (en) 2020-03-09 2021-09-16 Pfizer Inc. Fusion proteins and uses thereof
EP4130039A4 (en) 2020-03-23 2024-07-31 Bio-Thera Solutions, Ltd. DEVELOPMENT AND APPLICATION OF AN IMMUNE CELL ACTIVATOR
US20230035733A1 (en) * 2020-03-26 2023-02-02 Dusa Pharmaceuticals, Inc. Management of dermal neurofibromatosis lesions
AU2021256226A1 (en) 2020-04-17 2022-11-17 Hutchison Medipharma Limited Anti-OX40 antibody and uses thereof
CA3176826A1 (en) 2020-05-04 2021-11-11 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
TW202208616A (zh) 2020-05-04 2022-03-01 美商艾歐凡斯生物治療公司 改良之腫瘤反應性ｔ細胞的選擇
CA3177717A1 (en) 2020-05-13 2021-11-18 Adagene Ag Compositions and methods for treating cancer
KR20230008197A (ko) 2020-05-13 2023-01-13 화이자 인코포레이티드 암을 치료하기 위한 방법, 요법 및 용도
MX2023000662A (es) 2020-07-17 2023-02-27 Pfizer Anticuerpos terapeuticos y sus usos.
IL300884A (en) 2020-09-14 2023-04-01 Pfizer Treatment methods and uses for cancer treatment
US20230372397A1 (en) 2020-10-06 2023-11-23 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
CN114515335A (zh) 2020-11-19 2022-05-20 百奥泰生物制药股份有限公司 抗ox40抗体在治疗肿瘤或癌症中的应用
US20220168293A1 (en) 2020-12-02 2022-06-02 Pfizer Inc. Time to resolution of axitinib-related adverse events
WO2022125941A1 (en) 2020-12-11 2022-06-16 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
WO2022130206A1 (en) 2020-12-16 2022-06-23 Pfizer Inc. TGFβr1 INHIBITOR COMBINATION THERAPIES
WO2022133140A1 (en) 2020-12-17 2022-06-23 Iovance Biotherapeutics, Inc. Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
WO2022133149A1 (en) 2020-12-17 2022-06-23 Iovance Biotherapeutics, Inc. Treatment of cancers with tumor infiltrating lymphocytes
WO2022153161A1 (en) 2021-01-14 2022-07-21 Pfizer Inc. Treatment of cancer using a prmt5 inhibitor
CA3207359A1 (en) 2021-02-05 2022-08-11 Cecile Chartier-Courtaud Adjuvant therapy for cancer
CN116917273A (zh) 2021-03-02 2023-10-20 葛兰素史克知识产权发展有限公司 作为dnmt1抑制剂的经取代的吡啶
US20240182594A1 (en) * 2021-03-19 2024-06-06 KSQ Therapeutics, Inc. Uses of antagonist, non-depleting ox40 antibodies
KR20240032711A (ko) 2021-03-25 2024-03-12 이오반스 바이오테라퓨틱스, 인크. T-세포 공배양 효능 검정 및 세포 치료제와 함께 사용하기 위한 방법 및 조성물
US20240166747A1 (en) 2021-03-31 2024-05-23 Glazosmithkline Intellectual Property Development Limited Antigen binding proteins and combinations thereof
JP2024515189A (ja) 2021-04-19 2024-04-05 アイオバンス バイオセラピューティクス，インコーポレイテッド 細胞免疫療法におけるキメラ共刺激受容体、ケモカイン受容体、及びそれらの使用
WO2022245754A1 (en) 2021-05-17 2022-11-24 Iovance Biotherapeutics, Inc. Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
EP4377446A1 (en) 2021-07-28 2024-06-05 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
AU2022228085A1 (en) 2021-09-07 2023-03-23 Joy Global Underground Mining Llc Support for drilling and bolting tool
JP2024534581A (ja) 2021-09-24 2024-09-20 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球のための拡張プロセス及び薬剤
AR127482A1 (es) 2021-10-27 2024-01-31 Iovance Biotherapeutics Inc Sistemas y métodos para coordinar la fabricación de células para inmunoterapia específica de paciente
CA3237410A1 (en) 2021-11-10 2023-05-19 Friedrich Graf Finck VON FINCKENSTEIN Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
CA3240585A1 (en) 2021-12-17 2023-06-22 Wenfeng Xu Anti-ox40 antibodies, multispecific antibodies and methods of use
EP4448579A4 (en) 2021-12-17 2026-02-18 Shanghai Henlius Biotech Inc ANTI-OX40 ANTIBODIES AND METHODS OF USE
CA3243416A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. TUMOR INFILTRATION LYMPHOCYTES MODIFIED TO EXPRESS PAYLOADS
CA3248034A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. METHODS FOR EXPANSION OF TIL CELLS BY MEANS OF SPECIFIC CYTOKINE COMBINATIONS AND/OR AKT INHIBITOR TREATMENT
WO2023218320A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Anti-lymphotoxin beta receptor antibodies and methods of use thereof
CA3259654A1 (en) 2022-06-17 2023-12-21 Pfizer Inc. IL-12 VARIANTS, ANTI-PD1 ANTIBODIES, FUSING PROTEINS AND THEIR USES
WO2024003773A1 (en) 2022-07-01 2024-01-04 Pfizer Inc. 2,7-naphthyridine compounds as mastl inhibitors
JP2025525406A (ja) 2022-07-05 2025-08-05 ファイザー・インク ピリド［４，３－ｄ］ピリミジン化合物
EP4565683A1 (en) 2022-08-01 2025-06-11 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
WO2024074977A1 (en) 2022-10-04 2024-04-11 Pfizer Inc. Substituted 1 h-pyrazolo-pyridine and-pyrimidine compounds
EP4604961A1 (en) 2022-10-18 2025-08-27 Pfizer Inc. Compounds for the treatment of cancer
WO2024105563A1 (en) 2022-11-16 2024-05-23 Pfizer Inc. Substituted bicyclic pyridone derivatives
WO2024151885A1 (en) 2023-01-13 2024-07-18 Iovance Biotherapeutics, Inc. Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
WO2024209339A1 (en) 2023-04-05 2024-10-10 Pfizer Inc. Pyrido[4,3-d]pyrimidine compounds
WO2024213979A1 (en) 2023-04-10 2024-10-17 Pfizer Inc. Pyrido[4,3-d]pyrimidine compounds
WO2024218686A1 (en) 2023-04-20 2024-10-24 Pfizer Inc. Pyrido[4,3-d]pyrimidine compounds
TW202509071A (zh) 2023-05-12 2025-03-01 丹麥商珍美寶股份有限公司 能夠與ｏｘ４０結合之抗體、其變異體及其用途
WO2025032521A1 (en) 2023-08-10 2025-02-13 Pfizer Inc. Methods, therapies and uses for treating cancer
WO2025094035A1 (en) 2023-11-01 2025-05-08 Pfizer Inc. Toll-like receptor agonists and conjugates thereof
WO2025101484A1 (en) 2023-11-06 2025-05-15 Iovance Biotherapeutics, Inc. Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
TW202540189A (zh) 2023-11-30 2025-10-16 德商生物新技術公司 在組合療法中能夠結合ｏｘ４０之抗體

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US191293A (en) 1877-05-29 Improvement in car wheels and axles
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
FI903489A0 (fi) 1988-11-11 1990-07-10 Medical Res Council Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
DK0616640T3 (da) 1991-12-02 2004-12-20 Medical Res Council Fremstilling af anti-selv antistoffer fra repertoirer af antistofsegmenter og fremvist på fag
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
DK0698097T3 (da) 1993-04-29 2001-10-08 Unilever Nv Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
US5994619A (en) 1996-04-01 1999-11-30 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Production of chimeric bovine or porcine animals using cultured inner cell mass cells
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
EP1997893A1 (en) * 1998-02-24 2008-12-03 Sisters of Providence in Oregon Compositions containing an OX-40 receptor binding agent or a nucleic acid encoding the same and methods for enhancing antigen-specific immune response
DK2112166T3 (en) 1998-12-23 2019-02-04 Pfizer Human monoclonal antibodies to CTLA-4
IL147765A0 (en) 1999-07-29 2002-08-14 Medarex Inc HUMAN MONOCLONAL ANTIBODIES TO HER2/neu
JP3523245B1 (ja) 2000-11-30 2004-04-26 メダレックス，インコーポレーテッド ヒト抗体作製用トランスジェニック染色体導入齧歯動物
EP2796468A2 (en) 2001-01-05 2014-10-29 Pfizer Inc Antibodies to insulin-like growth factor I receptor
CA2436326C (en) 2001-01-09 2012-08-14 Merck Patent Gesellschaft Mit Beschraenkter Haftung Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
CA2447851C (en) 2001-06-28 2012-08-28 Domantis Limited Dual-specific ligand and its use
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
DE60317677T2 (de) * 2002-06-13 2008-10-30 Crucell Holland B.V. Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung
EP1517921B1 (en) 2002-06-28 2006-06-07 Domantis Limited Dual specific ligands with increased serum half-life
EP1578801A2 (en) 2002-12-27 2005-09-28 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
JP4889493B2 (ja) 2003-05-14 2012-03-07 ドマンティス リミテッド ポリペプチドレパートリーから可逆的にアンフォールドするポリペプチドを回収するための方法
SI1639011T1 (sl) 2003-06-30 2009-04-30 Domantis Ltd Pegilirana protitelesa z enojno domeno (dAb)
KR101333449B1 (ko) 2003-12-10 2013-11-26 메다렉스, 엘.엘.시. Ｉｐ―１０ 항체 및 그의 용도
EP1846454A2 (en) * 2004-09-30 2007-10-24 Medarex, Inc. Human monoclonal antibodies to fc gamma receptor ii (cd32)
EP1814568A4 (en) * 2004-10-29 2009-08-12 Univ Southern California COMBINATION IMMUNOTHERAPY AGAINST CANCER WITH COSTIMULATORY MOLECULES
WO2006055697A2 (en) 2004-11-17 2006-05-26 Board Of Regents, The University Of Texas System Cancer immunotherapy incorporating p53
AU2005325801A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
US7189097B2 (en) 2005-02-11 2007-03-13 Winchester Electronics Corporation Snap lock connector
JP2008542354A (ja) 2005-06-03 2008-11-27 ファイザー・プロダクツ・インク 癌治療におけるｅｒｂＢ２阻害剤と他の治療薬の併用
JP2006345852A (ja) * 2005-06-16 2006-12-28 Virxsys Corp 抗体複合体
WO2007062093A2 (en) 2005-11-22 2007-05-31 Incyte Corporation Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
TWI461436B (zh) * 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
AU2006317242A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
HUE032735T2 (en) * 2007-12-14 2017-10-30 Bristol Myers Squibb Co Binding molecules for the human OX40 receptor

Also Published As

Publication number Publication date
EP2851374A1 (en) 2015-03-25
TW200932268A (en) 2009-08-01
PT2242771E (pt) 2013-08-29
HRP20141188T8 (en) 2015-05-22
US20090214560A1 (en) 2009-08-27
ES2526887T3 (es) 2015-01-16
SI2594590T1 (sl) 2015-03-31
IL239674A (en) 2017-08-31
ES2628093T3 (es) 2017-08-01
JP2011505836A (ja) 2011-03-03
PH12015500806B1 (en) 2015-12-02
PL2242771T3 (pl) 2013-12-31
JP6248024B2 (ja) 2017-12-13
CN101918447A (zh) 2010-12-15
WO2009079335A1 (en) 2009-06-25
IL239674A0 (en) 2015-08-31
CA2707773A1 (en) 2009-06-25
JP2017114866A (ja) 2017-06-29
SI2851374T1 (sl) 2017-08-31
EP2851374B1 (en) 2017-05-03
DK2242771T3 (da) 2013-08-26
KR101577843B1 (ko) 2015-12-16
CN101918447B (zh) 2014-06-11
US20180057600A1 (en) 2018-03-01
PL2594590T3 (pl) 2015-05-29
AU2008338591B8 (en) 2014-02-20
US9028824B2 (en) 2015-05-12
EP2594590A1 (en) 2013-05-22
IL206297A0 (en) 2010-12-30
US20120225086A1 (en) 2012-09-06
BRPI0820875B1 (pt) 2021-10-19
SG186656A1 (en) 2013-01-30
AR109355A2 (es) 2018-11-21
IL206297A (en) 2016-06-30
HRP20141188T1 (en) 2015-03-13
SG10201604770VA (en) 2016-08-30
CA2949772A1 (en) 2009-06-25
JP5761997B2 (ja) 2015-08-12
PA8807601A1 (es) 2009-09-17
MX2010006466A (es) 2010-09-28
ZA201003579B (en) 2011-07-27
RU2010129045A (ru) 2012-01-20
AU2008338591B2 (en) 2014-01-23
DK2594590T3 (en) 2015-01-12
US8236930B2 (en) 2012-08-07
EP2242771A1 (en) 2010-10-27
JP2015110558A (ja) 2015-06-18
CO6280541A2 (es) 2011-05-20
AU2008338591A8 (en) 2014-02-20
DK2851374T3 (en) 2017-06-19
BRPI0820875A2 (pt) 2015-06-16
US20220002428A1 (en) 2022-01-06
EP2242771B1 (en) 2013-07-17
PT2851374T (pt) 2017-06-20
AU2008338591A1 (en) 2009-06-25
US10196452B2 (en) 2019-02-05
JP2019030313A (ja) 2019-02-28
CL2008003706A1 (es) 2009-06-12
IL245876A (en) 2017-08-31
PH12015500806A1 (en) 2015-12-02
PE20091269A1 (es) 2009-09-09
ES2425269T3 (es) 2013-10-14
JP6420379B2 (ja) 2018-11-07
HUE032735T2 (en) 2017-10-30
SI2242771T1 (sl) 2013-09-30
AR069681A1 (es) 2010-02-10
EP3239178A1 (en) 2017-11-01
KR20100102657A (ko) 2010-09-24
US20150218279A1 (en) 2015-08-06
IL245876A0 (en) 2016-07-31
CA2707773C (en) 2017-01-10
EP2594590B1 (en) 2014-11-12
PT2594590E (pt) 2015-01-14
US7960515B2 (en) 2011-06-14
US20110206681A1 (en) 2011-08-25
US20190135932A1 (en) 2019-05-09
US9840562B2 (en) 2017-12-12
UY31533A1 (es) 2009-08-03

Similar Documents

Publication Publication Date Title
KR101577843B1 (ko) 인간 ｏｘ４０ 수용체에 대한 결합 분자
AU2018202095B2 (en) Binding Molecules to the Human OX40 Receptor
HK1146415A (en) Binding molecules to the human ox40 receptor
HK1146415B (en) Binding molecules to the human ox40 receptor
AU2014202213A1 (en) Binding Molecules to the Human OX40 Receptor

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20150522

Application number text: 1020107015527

Filing date: 20100713

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20150619

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20150717

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20151222

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20150717

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I